Next Article in Journal
Two Cytoplasmic Acylation Sites and an Adjacent Hydrophobic Residue, but No Other Conserved Amino Acids in the Cytoplasmic Tail of HA from Influenza A Virus Are Crucial for Virus Replication
Next Article in Special Issue
Innate Immunity and Immune Evasion by Enterovirus 71
Previous Article in Journal
Structure of the Receptor-Binding Carboxy-Terminal Domain of the Bacteriophage T5 L-Shaped Tail Fibre with and without Its Intra-Molecular Chaperone
Previous Article in Special Issue
Molecular Epidemiology of Human Rhinoviruses and Enteroviruses Highlights Their Diversity in Sub-Saharan Africa
Article Menu

Export Article

Open AccessReview
Viruses 2015, 7(12), 6441-6457; doi:10.3390/v7122949

Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines

1
,
1,2,* and 1,3,*
1
Animal Health Biotechnology, Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 117604 Singapore
2
College of Animal Sciences, Zhejiang University, Yuhangtang Road 866, Hangzhou 310013, China
3
Department of Microbiology Faculty of Medicine, National University of Singapore, 117604 Singapore
*
Authors to whom correspondence should be addressed.
Academic Editor: George Belov
Received: 29 September 2015 / Revised: 30 November 2015 / Accepted: 1 December 2015 / Published: 8 December 2015
(This article belongs to the Special Issue Recent Progress in Enterovirus Research)
View Full-Text   |   Download PDF [370 KB, uploaded 8 December 2015]   |  

Abstract

Enterovirus 71 (EV71) is a group of viruses that belongs to the Picornaviridae family, which also includes viruses such as polioviruses. EV71, together with coxsackieviruses, is widely known for its association with Hand Foot Mouth Disease (HFMD), which generally affects children age five and below. Besides HFMD, EV71 can also trigger more severe and life-threatening neurological conditions such as encephalitis. Considering the lack of a vaccine and antiviral drug against EV71, together with the increasing spread of these viruses, the development of such drugs and vaccines becomes the top priority in protecting our younger generations. This article, hence, reviews some of the recent progress in the formulations of anti-therapeutics and vaccine generation for EV71, covering (i) inactivated vaccines; (ii) baculovirus-expressed vaccines against EV71; (iii) human intravenous immunoglobulin (IVIg) treatment; and (iv) the use of monoclonal antibody therapy as a prevention and treatment for EV71 infections. View Full-Text
Keywords: enterovirus 71; vaccines; anti-therapeutics; human intravenous immunoglobulin; baculovirus; monoclonal antibodies; inactivated vaccines enterovirus 71; vaccines; anti-therapeutics; human intravenous immunoglobulin; baculovirus; monoclonal antibodies; inactivated vaccines
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ng, Q.; He, F.; Kwang, J. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Viruses 2015, 7, 6441-6457.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top